Matthew Weston

Stock Analyst at UBS

(0.06)
# 3,982
Out of 4,670 analysts
1
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:

Stocks Rated by Matthew Weston

AstraZeneca
Nov 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $65.63
Upside: -